NASDAQ:CRTX Cortexyme (CRTX) Stock Price, News & Analysis → Pentagon contract could send this $2 AI stock soaring (From Behind the Markets) (Ad) Free CRTX Stock Alerts $1.06 +0.01 (+0.95%) (As of 04/22/2024 ET) Add Compare Share Share Today's Range$1.00▼$1.1050-Day Range$0.99▼$1.9552-Week Range$1.78▼$40.66Volume57,652 shsAverage Volume620,672 shsMarket Capitalization$31.96 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartCompetitorsFinancialsInsider TradesSocial MediaStock AnalysisChartCompetitorsFinancialsInsider TradesSocial Media Get Cortexyme alerts: Email Address Ad Behind the MarketsPentagon contract could send this $2 AI stock soaringWhenever the Department of Defense awards a major AI contract... Early investors could see dramatic returns virtually overnight. That's how my readers were able to cash in gains like 133% in just four months on C3.ai...Get all the info here >>> About Cortexyme Stock (NASDAQ:CRTX)Cortexyme, Inc., a clinical stage biopharmaceutical company, focuses on developing therapeutics for Alzheimer's and other degenerative diseases. Its lead drug candidate is atuzaginstat (COR388), an orally administered brain-penetrating small molecule gingipain inhibitor, which is in Phase II/III clinical trial for use in patients with mild to moderate Alzheimer's disease, as well as for the treatment of oral squamous cell carcinoma, periodontitis, and coronavirus infection. The company was incorporated in 2012 and is headquartered in South San Francisco, California.Read More CRTX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart CRTX Stock News HeadlinesAugust 1, 2022 | marketscreener.comCortexyme : Quince Therapeutics Details Strategic Growth Plan with Launch of New Corporate Name - Form 8-K - Marketscreener.comJuly 27, 2022 | marketscreener.comCortexyme Completes Phase 1 Single, Multiple Ascending Dose Trial of Potential Alzheimer's Disease Treatment - Marketscreener.comApril 23, 2024 | Behind the Markets (Ad)Pentagon contract could send this $2 AI stock soaringWhenever the Department of Defense awards a major AI contract... Early investors could see dramatic returns virtually overnight. That's how my readers were able to cash in gains like 133% in just four months on C3.ai...July 27, 2022 | businesswire.comCortexyme Successfully Completes Phase 1 Single and Multiple Ascending Dose Clinical Trial of COR588 - Business WireJuly 27, 2022 | businesswire.comCortexyme Corporate Name Change to Quince Therapeutics to Take Effect on August 1, 2022 - Business WireJuly 27, 2022 | marketscreener.comCortexyme Corporate Name Change to Quince Therapeutics to Take Effect on August 1, 2022 - Marketscreener.comJuly 27, 2022 | finance.yahoo.comCortexyme Successfully Completes Phase 1 Single and Multiple Ascending Dose Clinical Trial of COR588 - Yahoo FinanceJuly 27, 2022 | finance.yahoo.comCortexyme Successfully Completes Phase 1 Single and Multiple Ascending Dose Clinical Trial of COR588April 23, 2024 | Behind the Markets (Ad)Pentagon contract could send this $2 AI stock soaringWhenever the Department of Defense awards a major AI contract... Early investors could see dramatic returns virtually overnight. That's how my readers were able to cash in gains like 133% in just four months on C3.ai...July 27, 2022 | finance.yahoo.comCortexyme Corporate Name Change to Quince Therapeutics to Take Effect on August 1, 2022July 22, 2022 | streetinsider.comCortexyme (CRTX) Announces Resignation of EVP of Research and Development - StreetInsider.comJune 26, 2022 | gurufocus.comBragar Eagel & Squire, PC Is Investigating Agrify, CareDx, Medallion, and Cortexyme and Encourages Investors to Contact the Firm - GuruFocus.comJune 21, 2022 | benzinga.comCortexyme Announces Preclinical Data Demonstrating Efficacy Of Cor803 For The Treatment Of Coronavirus In - BenzingaJune 21, 2022 | nasdaq.comCortexyme : Preclinical Data Show Efficacy Of COR803 For Coronavirus Infections Treatment - NasdaqJune 21, 2022 | finance.yahoo.comCortexyme Announces Preclinical Data Demonstrating Efficacy of COR803 for the Treatment of Coronavirus InfectionsJune 13, 2022 | businesswire.comCortexyme Appoints June Bray to its Board of Directors - Business WireJune 13, 2022 | finance.yahoo.comCortexyme Appoints June Bray to its Board of Directors - Yahoo FinanceJune 13, 2022 | finance.yahoo.comCortexyme Appoints June Bray to its Board of DirectorsJune 11, 2022 | marketscreener.comCortexyme, Inc. Announces Resignation of Christopher Lowe as Chief Financial Officer - Marketscreener.comJune 10, 2022 | marketscreener.comCortexyme : Statement of Changes in Beneficial Ownership (Form 4) - Marketscreener.comMay 22, 2022 | businesswire.comCortexyme Successfully Completes Acquisition of Novosteo - Business WireMay 20, 2022 | nasdaq.comThis Is the Worst Type of Credit Card for Most Consumers - NasdaqMay 20, 2022 | finance.yahoo.comPPG Showcases Innovations in Paints, Coatings, Specialty Materials That Enhance Sustainability, Efficiency, Mobility - Yahoo FinanceMay 20, 2022 | marketscreener.comCortexyme : Completion of Acquisition or Disposition of Assets - Form 8-K - Marketscreener.comMay 20, 2022 | finance.yahoo.comCortexyme Successfully Completes Acquisition of Novosteo - Yahoo FinanceMay 20, 2022 | finance.yahoo.comCortexyme Appoints Dr. Philip Low to Its Board of DirectorsMay 13, 2022 | nasdaq.comPre-market Movers: EBET, AFRM, CELU, FIGS, LLAP… - NasdaqSee More Headlines Receive CRTX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Cortexyme and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/09/2021Today4/23/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological Products, Except Diagnostic Sub-IndustryHealth Care Technology Current SymbolNASDAQ:CRTX CUSIP21924P10 CIK1145404 Webwww.cortexyme.com Phone(650) 910-5717FaxN/AEmployees55Year Founded2012Profitability EPS (Most Recent Fiscal Year)($2.97) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-89,940,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-70.96% Return on Assets-63.53% Debt Debt-to-Equity RatioN/A Current Ratio9.92 Quick Ratio9.92 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$3.97 per share Price / Book0.27Miscellaneous Outstanding Shares30,151,000Free Float21,739,000Market Cap$31.96 million OptionableNot Optionable Beta1.40 Social Links 7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed InvestorsAs the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.Get This Free Report Key ExecutivesDr. Leslie J. Holsinger Ph.D. (Age 57)Exec. VP of R&D Comp: $603.85kDr. Dirk Thye M.D. (Age 52)CEO & Director Mr. Ted Monohon (Age 56)VP of Fin., Principal Financial Officer & Chief Accounting Officer Mr. Brendan Hannah M.B.A.Chief Bus. OfficerDr. Karen L. Smith L.L.M (Age 54)L.L.M., M.B.A., M.D., PH.D., Chief Medical Officer Key CompetitorsIkena OncologyNASDAQ:IKNAGenenta ScienceNASDAQ:GNTAAligos TherapeuticsNASDAQ:ALGSTurnstone BiologicsNASDAQ:TSBXJATT AcquisitionNYSE:JATTView All Competitors CRTX Stock Analysis - Frequently Asked Questions How have CRTX shares performed in 2024? Cortexyme's stock was trading at $1.05 on January 1st, 2024. Since then, CRTX shares have increased by 1.0% and is now trading at $1.06. View the best growth stocks for 2024 here. How were Cortexyme's earnings last quarter? Cortexyme, Inc. (NASDAQ:CRTX) issued its earnings results on Monday, August, 9th. The biopharmaceutical company reported ($0.74) earnings per share for the quarter, beating analysts' consensus estimates of ($0.79) by $0.05. What other stocks do shareholders of Cortexyme own? Based on aggregate information from My MarketBeat watchlists, some companies that other Cortexyme investors own include ADMA Biologics (ADMA), Gran Tierra Energy (GTE), Bionano Genomics (BNGO), DHT (DHT), EnLink Midstream (ENLC), Golar LNG Partners (GMLP), Matinas BioPharma (MTNB), Organigram (OGI), Pennsylvania Real Estate Investment Trust (PEI) and Tilly's (TLYS). When did Cortexyme IPO? Cortexyme (CRTX) raised $75 million in an initial public offering (IPO) on Thursday, May 9th 2019. The company issued 4,400,000 shares at $16.00-$18.00 per share. BofA Merrill Lynch and Credit Suisse acted as the underwriters for the IPO and Canaccord Genuity and JMP Securities were co-managers. How do I buy shares of Cortexyme? Shares of CRTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:CRTX) was last updated on 4/23/2024 by MarketBeat.com Staff From Our PartnersThe A.I. story nobody is telling you (Read ASAP)TradeSmithHealthcare Takes A Big Step Forward With The Help Of AIThe Bull ReportThis Apple-like Innovator is Revolutionizing HealthcareWall Street Startop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsDon’t Miss Out on the AI Gold Rush That’s Just Getting StartedBanyan Hill PublishingExposed: 10 CENT Crypto to Explode April 20th?True Market InsidersIs Tesla going out of business?DTI Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cortexyme, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
